EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North study

Tadakazu Hisamatsu, Toshimitsu Fujii, Hiroshi Nakase, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Seika Inoue, Kazuhiro Toriyama, Dong Wang, Yoko Uchikawa, Go Fujimoto, Toshifumi Hibi

Intestinal Research · 10.07.2026

DOI: 10.5217/ir.2026.00031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intestinal Research, online erschienen am 10.07.2026. Verfasst von Tadakazu Hisamatsu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Mitaka, Japan. thisamatsu@ks.kyorin-u.ac.jp. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Inflammatory bowel diseasesOzanimodSphingosine 1-phosphate receptor modulatorsUlcerative colitis

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Mitaka, Japan. thisamatsu@ks.kyorin-u.ac.jp.
  • Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Sapporo Medical University, Sapporo, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Gastroenterology, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.

Zitieren

APA

Hisamatsu, T., Fujii, T., Nakase, H., Matsuoka, K., Saruta, M., Kobayashi, T., Inoue, S., Toriyama, K., Wang, D., Uchikawa, Y., Fujimoto, G., & Hibi, T. (2026). Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North study. Intestinal Research. https://doi.org/10.5217/ir.2026.00031

Vancouver

Hisamatsu T, Fujii T, Nakase H, Matsuoka K, Saruta M, Kobayashi T, et al. Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North study. Intestinal Research. 2026. doi:10.5217/ir.2026.00031

BibTeX
@article{Hisamatsu2026,
  author = {Hisamatsu, Tadakazu and Fujii, Toshimitsu and Nakase, Hiroshi and Matsuoka, Katsuyoshi and Saruta, Masayuki and Kobayashi, Taku and Inoue, Seika and Toriyama, Kazuhiro and Wang, Dong and Uchikawa, Yoko and Fujimoto, Go and Hibi, Toshifumi},
  title = {Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North study},
  journal = {Intestinal Research},
  year = {2026},
  doi = {10.5217/ir.2026.00031}
}
Kostenlos starten →